The Prophylaxis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome With Defibrotide After Hematopoietic Stem Cell Transplantation in Children : Single Center Experience
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved..
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is one of the most severe and life-threatening complications after hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is approved for adult and pediatric patients with VOD/SOS with renal or pulmonary dysfunction after HSCT in the United States, and for severe VOD/SOS post-HSCT in patients above 1 month of age in the European Union. Several studies have examined whether DF prophylaxis can reduce the incidence of VOD/SOS in high-risk patients. A total of 334 pediatric allogeneic HSCT were included in this study. All patients received DF at the dose of 25 mg/kg/d, from the first day of the conditioning regimen to the 30th day after transplantation for VOD/SOS prophylaxis. Seventeen patients (5.08%) developed VOD/SOS; 4 of these had moderate, while 13 had mild VOD/SOS. None of the patients were developed severe or very severe VOD/SOS. In conclusion, we showed that prophylactic intervention with DF lowered the incidence of VOD/SOS in high-risk pediatric patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Journal of pediatric hematology/oncology - 44(2022), 1 vom: 01. Jan., Seite e35-e39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karagun, Barbaros S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
438HCF2X0M |
|---|
| Anmerkungen: |
Date Completed 16.02.2022 Date Revised 02.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MPH.0000000000002379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335019145 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335019145 | ||
| 003 | DE-627 | ||
| 005 | 20231225224926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MPH.0000000000002379 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM335019145 | ||
| 035 | |a (NLM)34966102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karagun, Barbaros S |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Prophylaxis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome With Defibrotide After Hematopoietic Stem Cell Transplantation in Children |b Single Center Experience |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2022 | ||
| 500 | |a Date Revised 02.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is one of the most severe and life-threatening complications after hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is approved for adult and pediatric patients with VOD/SOS with renal or pulmonary dysfunction after HSCT in the United States, and for severe VOD/SOS post-HSCT in patients above 1 month of age in the European Union. Several studies have examined whether DF prophylaxis can reduce the incidence of VOD/SOS in high-risk patients. A total of 334 pediatric allogeneic HSCT were included in this study. All patients received DF at the dose of 25 mg/kg/d, from the first day of the conditioning regimen to the 30th day after transplantation for VOD/SOS prophylaxis. Seventeen patients (5.08%) developed VOD/SOS; 4 of these had moderate, while 13 had mild VOD/SOS. None of the patients were developed severe or very severe VOD/SOS. In conclusion, we showed that prophylactic intervention with DF lowered the incidence of VOD/SOS in high-risk pediatric patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Polydeoxyribonucleotides |2 NLM | |
| 650 | 7 | |a defibrotide |2 NLM | |
| 650 | 7 | |a 438HCF2X0M |2 NLM | |
| 700 | 1 | |a Akbas, Tuana |e verfasserin |4 aut | |
| 700 | 1 | |a Erbey, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Sasmaz, İlgen |e verfasserin |4 aut | |
| 700 | 1 | |a Antmen, Bulent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pediatric hematology/oncology |d 1998 |g 44(2022), 1 vom: 01. Jan., Seite e35-e39 |w (DE-627)NLM075145790 |x 1536-3678 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:e35-e39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MPH.0000000000002379 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2022 |e 1 |b 01 |c 01 |h e35-e39 | ||